Aerial shot of a group of people together, showcasing diversity.

While the pharmaceutical industry as a whole acknowledges the need for greater diversity in clinical trials, there is ongoing debate as to the best approach. What life sciences professionals tend to agree on is the fact that representation in clinical trials does not align with the demographic makeup of the total population.

The availability of demographic data — and using that data to inform future trials — is vital to improving representation and reducing inequities. It’s a vicious cycle: Sponsors need demographic data in order to make clinical trials more diverse, but they also need to disclose the data upfront.

Related resources

Aerial shot of a busy city intersection with cars and people.
MAY 23, 2023
Press Release

Introducing Citeline’s Sitetrove Diversity Module

Citeline’s new Sitetrove Diversity Module marries robust site and investigator intelligence with patient age, race and gender data, enabling data-driven decision making to support the diversification of clinical trials.

Accelerating Diversity Enrollment in a Phase III COVID-19 Clinical Trial
Use Case
Patient Engagement & Recruitment

Accelerating Diversity Enrollment in a Phase III COVID-19 Clinical Trial

A biotech need to rapidly meet diversity/inclusion goals for a high-profile Phase III COVID-19 trial. Citeline Connect helped the sponsor recover from a 72% decline in diversity-focused randomizations, delivering 20-25% of daily randomizations in 32 days.

A diverse group of people sitting in a waiting room together.
JUL 12, 2023
Patient Engagement & Recruitment

The Need for Clinical Trial Diversity: How We Got Here and Where We're Headed

Clinical trial diversity, the inclusion of underrepresented segments of the population in medical research, is a crucial component of health equity.